Please assess the completion status of the following clinical trial:

Trial Title: A Safety, Efficacy, and Tolerability Trial of Pregabalin as Add-On Treatment in Pediatric Subjects <4 Years of Age With Partial Onset Seizures.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Subject must have 3 partial onset seizures in the month prior to screening.~* Subject must have 2 partial onset seizures during the 48 hour baseline phase.~* Signed Informed Consent.~* On 1-3 stable anti-epileptic drugs at screening.~Exclusion Criteria:~* Primary generalized seizures including clonic, tonic, clonic-tonic, absence, febrile seizures, and infantile spasms.~* Lennox-Gasteau, BECTS, and Dravet's syndrome.~* Status epliepticus within 1 year of screening.~* Any change in AED regimen with 7 days of screening.~* Progressive structural central nervous system (CNS) lesion or a progressive encephalopathy.~* Progressive errors of metabolism.

- Gender: ALL
- Minimum Age: 1 Month
- Maximum Age: 3 Years
- Healthy Volunteers: f

Study Arms:
- Study Drug Level 1 (Type: EXPERIMENTAL): None
- Study Drug Level 2 (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).